- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
|(Left to right: AIMBE President Dr. John Watson, Ph.D.; William H. Cork, vice president for research and development and chief technology officer at Nanosphere, Inc.; Cato T. Laurencin, M.D., Ph.D., Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the UConn School of Medicine, who received the 2009 Pierre Galletti Award, the highest honor bestowed annually by the AIMBE)|
Joins select group of medical and biological engineers and scientists
Nanosphere, Inc., (NASDAQ: NSPH), announced today that William H. Cork, the company's vice president for research and development and chief technology officer, was inducted into the American Institute of Medical and Biological Engineering's (AIMBE) prestigious College of Fellows at the Institute's annual event at the National Academy of Sciences in Washington, D.C. on February 12, 2009.
Mr. Cork was one of 96 newly elected Fellows of AIMBE, who joined the other 900 distinguished scientists and engineers as leaders in the development of biomedical devices and processes, treatment of diseases, and public policy related to all aspects of medical and biological engineering." In presenting the award to Mr. Cork, Jennifer Ayers, AIMBE's Executive Director, noted his accomplishments "for the development of highly sensitive molecular diagnostic systems based on nanotechnology as well as important blood separation technologies."
As head of research and development at Nanosphere, Mr. Cork led the company's effort to develop the The Verigene® System, an FDA-approved molecular diagnostics workstation that utilizes patented gold nanoparticle technology to detect nucleic acid and protein targets of interest for a variety of applications. Under Mr. Cork's leadership, Nanosphere also received the FDA's first clearance of a test to determine an individual's ability to metabolize the anti-coagulant medication warfarin, information critical to determining safe and appropriate dosing, on the nanotechnology based Verigene® System.
Commenting on Mr. Cork's induction into the AIMBE College of Fellows, William P. Moffitt, Nanosphere's president and chief executive officer, said, "We are extremely proud of Bill Cork and the cutting-edge research that he and his team have done in the development of our Verigene system. It is not surprising to us that his work has now been recognized by the American Institute of Medical and Biological Engineers, and he takes his rightful place among the leading scientists and engineers who have made their mark on the world of biomedical engineering."
Mr. Cork joined Nanosphere as vice president of research and development and chief technology officer at the inception of the company in 2000. Previously, he had developed a blood separation system at Baxter Healthcare, and holds numerous technology patents.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System for direct genomic and ultra-sensitive protein detection. This easy-to-use and cost-effective platform enables simple, low-cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL.
Safe Harbor Statement
Except for historical information, the matters discussed in this press release are "forward-looking statements" and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere's ability to develop commercially viable products; (ii) Nanosphere's ability to achieve profitability; (iii) Nanosphere's ability to produce and market its products; (iv) Nanosphere's ability to obtain regulatory approval of its products; (v) Nanosphere's ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere's ability to obtain additional financing, if and when necessary, to support its operations. Additional risks are discussed in the Company's current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please click here
William P. Moffitt
President and CEO
The Torrenzano Group
212-681-1700, Ext. 115
Copyright © Nanosphere, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information